What RevMed’s pancreatic cancer drug meant for one patient
-
By
-
Elaine Chen
-
Adam Feuerstein
-
Allison DeAngelis
-
June 4, 2026
-
Clinical Scorecard: The Impact of RevMed's Daraxonrasib on a Patient with Metastatic Pancreatic Cancer
At a Glance
| Category | Detail |
|---|
| Condition | Metastatic Pancreatic Cancer |
| Key Mechanisms | Daraxonrasib is being evaluated for its effects on metastatic pancreatic cancer. |
| Target Population | Patients with metastatic pancreatic cancer. |
| Care Setting | Clinical trial setting. |
Key Highlights
- Leanna Stokes was diagnosed with metastatic pancreatic cancer in 2023.
- Participation in RevMed's trial for daraxonrasib has affected her disease and life.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients participating in clinical trials for daraxonrasib.
Impact of daraxonrasib on disease progression and patient quality of life.
Clinical Best Practices
Related Resources & Content
